- Fee assured
- Awaiting verification
I gained my medical degree in Cape Town, South Africa and moved to the UK soon after. I trained in internal medicine at St Mary's in London before embarking on a career in Medical Oncology. I worked at the Royal Marsden and undertook research at The Institute of Cancer Research in London. I rotated through a number of teaching hospitals including the Royal Free, UCL and Mount Vernon before taking up a Consultant post in Medical Oncology in Oxford in 2016. I have a busy NHS practice covering all systemic treatments for breast and gynaecological malignancies across the the Thames Valley network. I am actively involved with research and am the principal investigator for several international and national clinical trials currently in set up in Oxford. In my spare time I enjoy being with my husband and young children, usually outdoors or on a boat.
Areas of interest
Advanced ovarian and endometrial cancer; use of targeted treatments in combination with chemotherapy. Novel agents including PARP inhibitors; clinical trials.
Early and advanced breast cancer; chemotherapy, biological therapy; bisphosphonates; targeted agents including CDK4/6 inhibitors; clinical trials
Current NHS consultant posts held
Consultant in Medical Oncology
Oxford University Hospitals NHS Foundation Trust
Novel combinations with chemotherapy and targeted therapies in first line, relapsed and platinum-resistant ovarian cancer.
Targeted treatments beyond chemotherapy for triple negative breast cancer. Earlier detection of relapse through non-invasive biopsy including ctDNA in breast cancer.
(Additional) Languages spoken
- Afrikaans - Conversational
Controversies in Gynaecological Cancer: Recurrent Ovarian Cancer; when to treat and how to assess , Springer 2014
Do Not Give Up – report of a woman treated for 22 relapses of ovarian cancer., Int J Gynecol cancer, Nov 2015
Maximal effort cytoreductive surgery for disseminated ovarian
cancer in a UK setting: challenges and possibilities
Arch Gynecol Obstet, 04 April 2016
Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations Published 15 July 2016
Phase 1/2a trial of intravenous BAL101553, a novel tumor checkpoint controller (TCC), in advanced solid tumors. Meeting: 2016 ASCO Annual Meeting Abstract No:2525 Citation: J Clin Oncol 34, 2016 (suppl; abstr 2525)
ESMO: 2017 abstract
Title: OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer
Acute Oncology and Ambulatory Care at the John Radcliffe Hospital – Introduction of Virtual Ward Rounds Poster and abstract at Society for Acute Medicine Conference for 2017
Reference number 4486280
Details of entry to specialist register
- Rene Roux, 2016
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.